Hepatitis, an inflammation of the liver, poses a significant global health burden. The progress in its management, particularly for Hepatitis B and C, has been remarkable over the past years. This article provides an overview of the latest advancements in hepatitis management.
Direct-acting antivirals (DAAs) have revolutionized Hepatitis C treatment. These medications target specific steps in the HCV life cycle, offering cure rates above 90%. Newer generations of DAAs, such as glecaprevir/pibrentasvir, offer pan-genotypic coverage and shorter treatment durations.
The Hepatitis B vaccine remains the cornerstone of Hepatitis B prevention. Additionally, antiviral medications like tenofovir and entecavir can suppress viral replication, preventing cirrhosis and liver cancer. Novel therapeutic strategies, including RNA interference therapies and immune modulators, are under investigation.
Hepatitis D, a severe form of viral hepatitis, is managed by pegylated interferon therapy. For Hepatitis E, ribavirin is the treatment of choice for chronic cases. Both conditions require further research to develop more effective treatments.
Non-invasive tools for liver fibrosis assessment, such as transient elastography (FibroScan) and serum biomarkers, are increasingly used in hepatitis management. These tools can reduce the need for liver biopsies, making disease monitoring safer and more accessible.
While significant strides have been made in hepatitis management, challenges persist, particularly in the areas of Hepatitis B cure, Hepatitis D treatment, and global access to DAAs for Hepatitis C. Ongoing research and commitment to hepatitis elimination are paramount to address these challenges. Healthcare professionals play a crucial role in this endeavor, and staying updated with the latest advancements is essential for effective patient care.
1.
The need for more Latinx participants in Alzheimer's trials is urgent.
2.
Study reveals crucial gaps in oral cancer awareness in Middle East and North Africa
3.
Disparities in use of MRI to detect prostate cancer: Race and location may influence testing
4.
In breast-conserving surgery, is micro-CT a useful tool for determining tumor margins?
5.
Study offers clearer picture of childhood brain tumor survival
1.
Revolutionizing Cancer Care: The Promise of Early Detection and Biomarkers
2.
The Oncologist’s Edge: Tools, Trials, and Tech Transforming Treatment
3.
Comprehensive Standards in Oncology for Modern Medicine
4.
Cardio-Oncology: Managing Heart Failure in Survivors of Cancer
5.
Practical Standards in Hematology for Healthcare Excellence
1.
Asian Symposium on Advancement in Hematology and Oncology (ASAHO)
2.
International Cancer Conference
3.
Asian Symposium on Advancement in Hematology and Oncology (ASAHO)
4.
Asian Symposium on Advancement in Hematology and Oncology
5.
Asian Symposium on Advancement in Hematology and Oncology
1.
Targeting Oncologic Drivers with Dacomitinib: A New Approach to Lung Cancer Treatment
2.
Revolutionizing Treatment of ALK Rearranged NSCLC with Lorlatinib - Part II
3.
Efficient Management of First line ALK-rearranged NSCLC - Part VIII
4.
Nimotozumab Plus Chemo-radiotherapy v/s Placebo Plus Chemo-radiotherapy in Locally Advanced Nasopharyngeal Carcinoma
5.
Breaking Ground: ALK-Positive Lung Cancer Front-Line Management - Part V
© Copyright 2026 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation